The business of extending healthy human life is moving from speculative science towards a potentially vast pharmaceutical market, with longevity biotech projected to generate $617 billion in annual global revenue by 2045, according to a new report from Longevity.Technology.

The forecast, however, is less a prediction of today’s industry than a measure of what the market could become if therapies targeting the biology of ageing gain regulatory approval and achieve widespread adoption.

Longevity.Technology’s Longevity Biotech Report 2026 tracks 781 companies and 3,580 therapeutic assets worldwide, with 3,036 assets individually modelled for its bottom-up analysis. More than 1,000 programmes are already in human trials, indicating that the sector has moved well beyond the laboratory stage.

Capital is following that pipeline. Investment in longevity biotech reached $18.4 billion in 2025 from $4.7 billion the previous year. In 2026, $12.1 billion has been invested. That puts more than $30 billion into the sector in less than two years, with funding increasingly concentrated in larger deals and companies with clinical programmes.

The report also identifies a substantial opportunity under existing regulatory pathways. Its bottom-up analysis estimates around $230 billion in risk-adjusted peak annual sales from therapies pursuing established disease indications. A further $173 billion could emerge if a dedicated gerotherapeutic pathway eventually allows interventions aimed directly at ageing biology.

The headline $617 billion figure rests on several assumptions: treatment beginning around age 45, pricing broadly comparable with current GLP-1 medicines, peak adoption of 35%, and a ten-year market diffusion period. Longevity.Technology models the first approval of a gerotherapeutic around 2035. Changing those assumptions materially changes the market size.

That caveat is central. Neither the FDA nor EMA currently recognises ageing as a standalone therapeutic indication, while questions around biomarkers, endpoints and trial design remain unresolved. 

Its significance, therefore, may lie less in the $617 billion headline than in what drives it: growing investment, increasingly mature clinical pipelines and a pharmaceutical industry beginning to treat ageing biology as a commercial opportunity.

The longevity market is not yet $617 billion. But the infrastructure for one is taking shape.

Reference: Longevity.Technology